Lifeward Ltd. — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Lifeward reported Q3 2026 revenue of $5.4M (down 12% YoY from $6.2M), with AlterG growing 18% to $3.6M but ReWalk revenue falling 43% to $1.7M due to transition from direct sales to channel-partner distribution. Operating loss widened to $6.0M from $3.1M YoY; net loss was $5.1M ($1.32/share, 3.84M shares weighted average) vs. $3.2M prior year. Gross margin collapsed to 27.4% from 43.7% YoY, driven by FX, tariffs, and revenue-sharing payments to Oramed under the March 2026 Oratech acquisition. Cash position improved to $4.5M (Sept 30) from $2.2M (Dec 31), reflecting $18.5M in financing activities YoY.
Why this rating
Revenue decline and margin compression are material relative to $10M market cap; ReWalk transition creates near-term headwind but strategic pivot toward partnerships; cash runway remains concerning given $16M operating burn in 9M 2026.
Tradability signal
NO TRADE
No trade: only ~$19k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · unknown $5.42 | +10 min · unknown $4.85 ▼ 10.52% | +30 min · unknown $4.91 ▼ 9.41% | +1 hr · unknown $4.92 ▼ 9.23% | +4 hrs · unknown $4.14 ▼ 23.62% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.